The differences in homeostasis model assessment values in type 2 diabetic patients with different lengths of history of diabetes

Abstract

Objective: Type 2 diabetes (T2DM) is characterized by the progressive deterioration of pancreatic islet β-cell function over time and insulin resistance. Knowing more about the differences in pancreatic islet function in T2DM patients who have had diabetes for different lengths of time can help improve therapy for T2DM. Subjects and methods: We conducted a cross-sectional study to compare islet β-cell function and insulin resistance in T2DM patients (n = 3,254) who had had diabetes for different lengths of time and those in normal controls (n = 794) using ANOVA and LSD analysis. Results: We found that compared with that in normal controls, HOMA-β in T2DM patients with a history of diabetes of less than 1 year was lower (approximately 52% of that of normal controls, p = 0.003), while HOMA-IR in these patients was higher (approximately 50% of that of normal controls, p = 0.007). Compared with that in other diabetic patients, HOMA-β in patients with a history of diabetes of more than 30 years was the lowest. HOMA-IR in patients with a history of diabetes of between 20 and 30 years was lower than that in other diabetic patients (p < 0.05). Conclusions: There were obvious decreases in HOMA-β and increases in HOMA-IR in T2DM patients with a history of diabetes of less than 1 year compared with those in normal controls. Therefore, early screening and intervention for T2DM might help improve islet function and delay the progression of diabetes. Arch

Effect of dietary fat intake and genetic risk on glucose and insulin-related traits in Brazilian young adults

“…In addition, our GRS was constructed based on 10 SNPs, which account for only a small proportion of the metabolic disease-related genetic variants. As HOMA is a widely validated clinical and epidemiological tool for assessing IR and β-cell function [74], like many other epidemiological studies [33,35,59], we also used HOMA-IR and HOMA-B as proxies for IR and insulin secretion, respectively. However, these measures are calculated only using fasting insulin and glucose values which might provide different estimates compared to methods based on dynamic measurements of insulin and glucose responses or those derived from clamp experiments [75].…”

Nutritional Biomarkers for Predicting Pancreatic Beta Cell Failure in Central Obesity

“…(6) Specifically, previous study showed that central obesity remained a significant predictor T2DM. (7) Interestingly, 43.8% of previously undiagnosed T2DM patients in Indonesia are with central obesity (8) and once T2DM diagnosed, at least 50% of pancreatic beta cell mass has decreased and continuously deteriorated along T2DM progression (9). When patients diagnosed at that point, actually it is already late.…”